- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CHINA YONGXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 32,900 | +0,80 % | Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024? | ||
| CSPC PHARMA | 0,620 | -2,21 % | M Stanley Cuts CSPC PHARMA TP to $6.6 w/ Lower EPS Forecasts | ||
| SELLAS LIFE SCIENCES | 1,172 | +3,72 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update | - Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 - - Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 14,845 | -5,54 % | Acadia Pharmaceuticals Inc - On Nov 18, Co Involuntarily Terminates COO Brendan Teehan | ||
| MADRIGAL PHARMACEUTICALS | 332,50 | -0,33 % | Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024? | ||
| CATALYST PHARMACEUTICALS | 19,880 | -3,54 % | Catalyst Pharmaceuticals Insider Trades Send A Signal | ||
| OPUS GENETICS | 0,952 | -1,35 % | Foundation Fighting Blindness: The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics | The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD)
RALEIGH, N.C., Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,058 | -3,33 % | ENZON PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse | Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,140 | -8,50 % | Viracta Therapeutics, Inc. - 8-K, Current Report | ||
| SAVARA | 3,120 | -3,11 % | Savara-Direktor Joseph McCracken erwirbt Stammaktien im Wert von 59.071 US-Dollar | ||
| GALECTIN THERAPEUTICS | 2,620 | +1,55 % | Galectin Therapeutics Inc.: Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting | ||
| BIODEXA PHARMACEUTICALS | 4,830 | +9,77 % | Biodexa Pharmaceuticals PLC: Result of General Meeting | November 22, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Result of General Meeting Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ: BDRX), a clinical stage biopharmaceutical... ► Artikel lesen | |
| SCICLONE PHARMACEUTICALS | - | - | SCICLONE PHARMA (06600): (1) PROPOSAL FOR THE PRIVATISATION OF SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED BY SILVER PEGASUS INVESTMENT LIMITED BY WAY ... | ||
| NOVABAY PHARMACEUTICALS | 0,080 | 0,00 % | NovaBay Pharmaceuticals, Inc. - 8-K, Current Report |
CHINA YONGXIN PHARMACEUTICALS INC gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHINA YONGXIN PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
